Woori IO and Sinopharm Sign NDA for China Market and Global Clinical Trials
Woori IO, a subsidiary of OSR Company, has entered into a strategic Non-Disclosure Agreement (NDA) with Chinese pharmaceutical giant Sinopharm to explore commercialization opportunities in mainland China. The partnership also outlines a framework for collaboration on global multicenter clinical trials, signaling a major expansion for OSR's therapeutic pipeline into the world's second-largest pharmaceutical market.